FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/Highlighting the comparative effectiveness and patient outcomes between once-weekly semaglutide and daily liraglutide for weight management in non-diabetic obese patients.
研究ライブラリに戻る
semaglutideliraglutide

Highlighting the comparative effectiveness and patient outcomes between once-weekly semaglutide and daily liraglutide for weight management in non-diabetic obese patients.

May 17, 2026
Share

元の論文

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.

Rubino Domenica M et al.JAMA2022
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、上記の元の論文から得られた見解をペプチド研究コミュニティ向けに読みやすく分解しています。私たちの目標は、最も重要な点 — 実践的な意味合い、証拠の強さ、そして継続的研究に対する影響 — を強調することです。

Weekly Semaglutide Outperforms Daily Liraglutide in Weight Loss for Non-Diabetic Obese Adults

Published: May 17, 2026 | Source: JAMA (2022) | Category: semaglutide, liraglutide

Overview

A recent study published in the Journal of the American Medical Association (JAMA) has shown that once-weekly subcutaneous semaglutide leads to significantly greater weight loss compared to daily liraglutide among adults with overweight or obesity but without diabetes. This finding is crucial for individuals seeking effective peptide therapies for weight management.

Study Background

Previous research had established the efficacy of both glucagon-like peptide-1 (GLP-1) analogues, semaglutide and liraglutide, in managing body weight. However, direct comparisons between these two treatments were lacking. The STEP 8 trial aimed to address this gap by comparing the effectiveness and safety profiles of once-weekly subcutaneous semaglutide at 2.4 mg versus daily liraglutide at 3.0 mg for weight management in non-diabetic obese adults.

What the Research Found

The study, conducted over a period of 68 weeks, involved 338 participants who were randomized to receive either once-weekly semaglutide (126 participants), daily liraglutide (127 participants), or placebo. The primary outcome was percentage change in body weight from baseline. By the end of the study period, those receiving semaglutide experienced an average weight loss of 15.8%, compared to 6.4% for those on liraglutide, representing a significant difference of -9.4 percentage points (p < 0.001). Additionally, more participants in the semaglutide group achieved clinically meaningful weight loss milestones: 72% reached at least 10% weight loss, compared to 35% for liraglutide.

What This Means for Peptide Users

For individuals looking to manage their body weight through peptide therapy and who do not have diabetes, the results suggest that semaglutide may be a more effective option than daily liraglutide. The once-weekly dosing of semaglutide could also offer greater convenience compared to the daily regimen required for liraglutide.

Limitations and Caveats

While the study provides compelling evidence, it is important to note several limitations. First, the trial had a relatively short follow-up period of 68 weeks, which may not fully capture long-term outcomes or side effects. Second, the study excluded participants with diabetes, limiting its applicability to this population. Lastly, the open-label design might have influenced participant behavior and reporting of adverse events.

How This Compares to Previous Research

Previous studies had shown that both semaglutide and liraglutide were effective in promoting weight loss; however, direct comparisons between these two treatments were limited. The STEP 8 trial provides a definitive comparison, highlighting the superior efficacy of semaglutide for non-diabetic obese adults.

Our Analysis

PeptideVault's analysis indicates that this study offers valuable insights into the comparative effectiveness of once-weekly semaglutide versus daily liraglutide for weight management in non-diabetic individuals. The significant difference in weight loss outcomes supports the potential benefits of semaglutide as a preferred treatment option. However, further research is needed to confirm these findings over longer periods and across diverse populations.

Key Takeaways

  • Greater Efficacy: Once-weekly semaglutide resulted in significantly more weight loss compared to daily liraglutide.
  • Convenience Factor: The once-weekly dosing of semaglutide offers a practical advantage for patients.
  • Further Research Needed: Long-term studies and investigations into the effects on diabetic populations are warranted.

Original Source

Citation: Rubino Domenica M, Greenway Frank L, Khalid Usman et al. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.. JAMA. DOI: 10.1001/jama.2021.23619

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

編集者の注

この分析はPeptide Contacts研究チームによって作成されました。情報確認のために常に元のソースをご確認ください。 元の論文 詳細な方法論とデータについては 元の出版物は以下で利用可能です PubMed.

関連研究

Comments

Sign in to join the discussion

この分析は査読済みの研究から生成され、教育目的のみで使用されます。医療アドバイスにはなりません。ペプチドベースの治療を使用する前に常に格付けされた医療専門家に相談してください。